UBS Group
NVAX icon

UBS Group’s Novavax NVAX Stock Holding History

UBS Group’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-27,900
Closed -$242K – 10972
2025
Q3 		$242K Hold
27,900
– – ﹤0.01% 6564
2025
Q2 		$176K Buy
+27,900
New +$185K ﹤0.01% 6808
2024
Q3 		– Sell
-36,700
Closed -$465K – 9895
2024
Q2 		$465K Buy
+36,700
New +$369K ﹤0.01% 5059
2023
Q1 		– Sell
-600
Closed -$6.17K – 10129
2022
Q4 		$6.17K Buy
+600
New +$10.6K ﹤0.01% 9072
2022
Q3 		– Sell
-29,000
Closed -$1.49M – 10736
2022
Q2 		$1.49M Sell
29,000
-10,000
-26% -$518K ﹤0.01% 3381
2022
Q1 		$2.87M Sell
39,000
-38,500
-50% -$3.43M ﹤0.01% 3095
2021
Q4 		$11.1M Buy
77,500
+47,500
+158% +$8.16M ﹤0.01% 2052
2021
Q3 		$6.22M Hold
30,000
– – ﹤0.01% 2444
2021
Q2 		$6.37M Buy
+30,000
New +$5.5M ﹤0.01% 2439
2016
Q1 		– Sell
-15
Closed -$3K – 8002
2015
Q4 		$3K Hold
15
– – ﹤0.01% 7892
2015
Q3 		$2K Hold
15
– – ﹤0.01% 8091
2015
Q2 		$3K Sell
15
-25
-63% -$4.39K ﹤0.01% 8076
2015
Q1 		$7K Sell
40
-440
-92% -$71.4K ﹤0.01% 7910
2014
Q4 		$57K Buy
+480
New +$50.2K ﹤0.01% 6326

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

UBS Group's NVAX Position: Q2 2026 in Review

UBS Group reduced its Novavax (NVAX) stake by 58% in Q2 2026, selling an estimated $23.4M and leaving 1,869,659 shares worth $17.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2822.

UBS Group first reported a position in NVAX in Q4 2014 and has held it in 47 quarters since. The position peaked at $39M in Q4 2024. 267 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • UBS Group held 1,869,659 shares of Novavax worth $17.6M as of Q2 2026.
  • UBS Group sold 2,608,042 Novavax shares in Q2 2026, an estimated $23.4M.
  • Novavax made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2822 holding.
  • UBS Group first reported a position in Novavax in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Novavax position peaked at $39M in Q4 2024.
  • 267 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.